<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2061">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05134337</url>
  </required_header>
  <id_info>
    <org_study_id>LOXO-BTK-20006</org_study_id>
    <secondary_id>J2N-OX-JZNC</secondary_id>
    <nct_id>NCT05134337</nct_id>
  </id_info>
  <brief_title>Study of the Effects of Itraconazole and Rifampin on LOXO-305 in Healthy Participants</brief_title>
  <official_title>A Phase 1, Open Label, Two-part, Fixed-sequence Drug Interaction Study to Investigate the Effect of Strong CYP3A4 Inhibitor (Itraconazole) and CYP3A4 Inducer (Rifampin) on the Pharmacokinetics of LOXO 305 in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Loxo Oncology, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to learn about how itraconazole and rifampin affect&#xD;
      LOXO-305 in healthy participants. Participation could last about 8 weeks.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 12, 2020</start_date>
  <completion_date type="Actual">October 30, 2020</completion_date>
  <primary_completion_date type="Actual">October 30, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess the impact of multiple oral doses of itraconazole on single oral dose pharmacokinetics (PK) of LOXO 305 by collecting/evaluating serum at protocol-specified time points: Maximum observed plasma concentration (Cmax)</measure>
    <time_frame>Pre-dose up to 168 hours post-dose</time_frame>
    <description>PK of LOXO-305</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess the impact of multiple oral doses of itraconazole on single oral dose PK of LOXO 305 by collecting/evaluating serum at protocol-specified time points: Area under the concentration-time curve from Hour 0 to last measurable concentration (AUC0-t)</measure>
    <time_frame>Pre-dose up to 168 hours post-dose</time_frame>
    <description>PK of LOXO-305</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess the impact of multiple oral doses of itraconazole on single oral dose PK of LOXO 305 by collecting/evaluating serum at protocol-specified time points: Area under the concentration-time curve extrapolated to infinity (AUC0-inf)</measure>
    <time_frame>Pre-dose up to 168 hours post-dose</time_frame>
    <description>PK of LOXO-305</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess the effect of multiple oral doses of rifampin on single oral dose PK of LOXO 305 by collecting/evaluating serum at protocol-specified time points: Cmax</measure>
    <time_frame>Pre-dose up to 168 hours post-dose</time_frame>
    <description>PK of LOXO-305</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess the effect of multiple oral doses of rifampin on single oral dose PK of LOXO 305 by collecting/evaluating serum at protocol-specified time points: AUC0-t</measure>
    <time_frame>Pre-dose up to 168 hours post-dose</time_frame>
    <description>PK of LOXO-305</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess the effect of multiple oral doses of rifampin on single oral dose PK of LOXO 305 by collecting/evaluating serum at protocol-specified time points: AUC0-inf</measure>
    <time_frame>Pre-dose up to 168 hours post-dose</time_frame>
    <description>PK of LOXO-305</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess the effect of a single oral dose of rifampin on single oral dose PK of LOXO-305 by collecting/evaluating serum at protocol-specified time points: Cmax</measure>
    <time_frame>Pre-dose up to 168 hours post-dose</time_frame>
    <description>PK of LOXO-305</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess the effect of a single oral dose of rifampin on single oral dose PK of LOXO-305 by collecting/evaluating serum at protocol-specified time points: Area under the concentration time curve from hour 0 to 24 hours postdose (AUC0-24)</measure>
    <time_frame>Pre-dose up to 168 hours post-dose</time_frame>
    <description>PK of LOXO-305</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Part 1 Period 1 (LOXO-305 Alone)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LOXO-305 administered orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 Period 2 (Itraconazole + LOXO-305)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Itraconazole + LOXO-305 co-administered orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 Period 1 (LOXO-305 Alone)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LOXO-305 administered orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 Period 2 (Rifampin + LOXO-305)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rifampin + LOXO-305 co-administered orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LOXO-305</intervention_name>
    <description>Oral LOXO-305</description>
    <arm_group_label>Part 1 Period 1 (LOXO-305 Alone)</arm_group_label>
    <arm_group_label>Part 1 Period 2 (Itraconazole + LOXO-305)</arm_group_label>
    <arm_group_label>Part 2 Period 1 (LOXO-305 Alone)</arm_group_label>
    <arm_group_label>Part 2 Period 2 (Rifampin + LOXO-305)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Itraconazole</intervention_name>
    <description>Oral itraconazole</description>
    <arm_group_label>Part 1 Period 2 (Itraconazole + LOXO-305)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifampin</intervention_name>
    <description>Oral rifampin</description>
    <arm_group_label>Part 2 Period 2 (Rifampin + LOXO-305)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males and females of non-childbearing potential.&#xD;
&#xD;
          -  Within body mass index (BMI) range 18.0 to 32.0 kilograms per square meter (kg/mÂ²).&#xD;
&#xD;
          -  Participants will be in good general health, based on medical history, physical&#xD;
             examination findings, vital signs, 12 lead electrocardiogram (ECG), or clinical&#xD;
             laboratory tests, as determined by the Investigator (or designee).&#xD;
&#xD;
          -  Able to comply with all study procedures, including the 19-night stay for those&#xD;
             participating in Part 1 or 24-night stay for those participating in Part 2 at the&#xD;
             Clinical Research Unit and follow-up phone call.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History or presence of any of the following, deemed clinically significant by the&#xD;
             Investigator (or designee), and/or Sponsor:&#xD;
&#xD;
               -  liver disease&#xD;
&#xD;
               -  pancreatitis&#xD;
&#xD;
               -  peptic ulcer disease&#xD;
&#xD;
               -  intestinal malabsorption&#xD;
&#xD;
               -  gastric reduction surgery&#xD;
&#xD;
               -  history or presence of clinically significant cardiovascular disease.&#xD;
&#xD;
          -  Participants with out-of-range, at-rest vital signs.&#xD;
&#xD;
          -  Abnormal laboratory values determined to be clinically significant by the Investigator&#xD;
             (or designee).&#xD;
&#xD;
          -  Clinically significant abnormality, as determined by the Investigator (or designee),&#xD;
             from physical examination.&#xD;
&#xD;
          -  Participation in any other investigational study drug trial involving administration&#xD;
             of any investigational drug in the past 30 days or 5 half-lives, whichever was longer,&#xD;
             prior to the first dose administration (Day 1).&#xD;
&#xD;
          -  Use or intention to use any prescription or over-the-counter medications within 14&#xD;
             days prior to the first dose administration (Day 1) and through end of trial.&#xD;
&#xD;
          -  History or presence, upon clinical evaluation, of any illness that, in the opinion of&#xD;
             the Investigator, would interfere with the ability to provide informed consent or&#xD;
             comply with study instructions, or that might confound the interpretation of the study&#xD;
             results, or put the participant at undue risk.&#xD;
&#xD;
          -  Donation of blood from 56 days prior to Screening, plasma or platelets from 4 weeks&#xD;
             prior to Screening.&#xD;
&#xD;
          -  Receipt of blood products within 2 months prior to Check-in (Day -1).&#xD;
&#xD;
          -  Significant history or clinical manifestation of any metabolic, allergic,&#xD;
             dermatological, hepatic, biliary, renal, hematological, pulmonary, cardiovascular&#xD;
             (including any prior history of cardiomyopathy or cardiac failure), gastrointestinal&#xD;
             (GI), neurological, or psychiatric disorder (as determined by the Investigator), or&#xD;
             cancer within the past 5 years (except localized basal cell, squamous, or in situ&#xD;
             cancer of the skin).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>RenÃ©e Ward, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Loxo Oncology, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance Clinical Research Unit</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 22, 2021</study_first_submitted>
  <study_first_submitted_qc>November 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 24, 2021</study_first_posted>
  <last_update_submitted>November 23, 2021</last_update_submitted>
  <last_update_submitted_qc>November 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Itraconazole</mesh_term>
    <mesh_term>Rifampin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

